AUS
NZ
UK
CA
USA
IND
Highlights
- Recce Pharmaceuticals reaches milestone in Phase II trial for R327G gel.
- Positive responses observed, with no reported Serious Adverse Events.
- Trial results demonstrate potential in addressing complex skin infections.
Recce Pharmaceuticals Ltd (ASX:RCE) has marked a significant milestone in its ongoing clinical trial for RECCE 327 (R327G), a topical gel aimed at treating Acute Bacterial Skin and Skin Structure Infections (ABSSSI). In this Phase II trial, Recce has successfully administered R327G to twenty out of thirty patients, advancing the study’s goal to assess the gel's efficacy in combating severe skin infections.
The data gathered thus far reveals promising outcomes, with participants responding positively to the treatment. Every patient treated has reported either a complete cure or significant improvement, underlining the gel’s potential effectiveness in managing ABSSSI and similar conditions.
Dr. Alan W. Dunton, Recce's Chief Medical Advisor, commented on the promising interim results, emphasizing that the strong response to R327G is a significant step forward in anti-infective therapies. "These interim results reflect a remarkable advancement in our journey to address critical unmet medical needs in anti-infective therapies," Dr. Dunton stated. He expressed optimism regarding the treatment’s trajectory as the Phase II trial nears completion, pointing to the positive outcomes as a testament to the gel's potential in treating complex bacterial infections, including diabetic foot infections.
A notable aspect of the trial is the absence of any Serious Adverse Events (SAEs), reinforcing the safety profile of R327G. This absence of negative side effects adds to the therapy’s appeal, as it demonstrates that the gel not only performs effectively but also maintains a strong safety record—a critical factor in developing new treatments.
Recce Pharmaceuticals’ recent progress has drawn attention within the medical and investment communities, with the company's stock responding positively. As of midday AEDT, Recce’s shares were trading at 45 cents, reflecting a slight increase following the announcement.
Recce Pharmaceuticals continues to monitor patient responses and analyze data from the trial, with the goal of further validating R327G’s efficacy and safety profile. The next steps include concluding the Phase II trial and preparing for subsequent stages of clinical testing, which will help define R327G’s potential as a treatment option for severe bacterial skin infections.
By advancing treatments like R327G, Recce Pharmaceuticals aims to address the pressing demand for new anti-infective therapies, positioning the company as a notable contributor in the fight against resistant bacterial infections.
